Nextrials and Allon Therapeutics Set New Benchmark for Releasing Clinical Trial Results
Allon uses Nextrials’ Prism to go from last patient visit to results in under seven weeks.
San Ramon, CA-June 16, 2008-Nextrials, a leader in clinical research software and services, today announced that its flagship Prism® clinical trial management software was used by Allon Therapeutics to successfully manage and analyze results of a Phase IIa trial of a novel treatment for Alzheimer’s disease. Using the Prism software, results from Allon’s nine-month, 16-site clinical trial were announced in less than seven weeks after the final patient visit-a notable achievement within the biopharmaceutical R&D community.
Karole Sutherland, Allon’s vice president, clinical operations, said Prism enabled Allon to institute efficiencies that improved collaboration, substantiated the data quality and accelerated the review and announcement of the trial results. “This was the first proof of human efficacy for our compound-and for an emerging company such as Allon Therapeutics, it was important to release high quality data as quickly as possible to our shareholders and to the investment and medical communities,” said Sutherland.
Sutherland added that unique Prism features, such as the patient randomization module, real-time project alerts and nightly data extracts, allowed Allon to track trial progress and data integrity on an ongoing basis. “Since it was a blinded trial, we did not know the outcome until the trial was closed. However, the responsiveness of the Nextrials team and the efficiencies provided by Prism ensured that the data was clean immediately upon database lock,” she said.
James Rogers, chief executive officer and cofounder of Nextrials, said the company was able to work closely with Allon to close the study and lock the database in record time. “Seeing Allon successfully release its study results to the public in less than seven weeks after the final patient visit gives us additional proof that Prism can be a powerful ally in shortening the time to market for novel drugs and therapeutics,” he said.
Attendees at the 44th Annual Meeting of the Drug Information Association, being held June 22–26 at the Boston (MA) Convention and Exhibition Center, can learn more about Nextrials’ Prism by visiting Booth 1817.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
